Clinical Trial Update: Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

The document reports a Phase 2 clinical trial update for Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in advanced or unresectable/metastatic non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Datopotamab Deruxtecan (Dato-DXd, DS-1062a) (datopotamab deruxtecan)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING